TABLE 2.
A | Hyp residues |
av. #Hyp | % change | |||||||
0 | 1 | 2 | 3 | 4 | 5 | 6 | ||||
pEAQ-IgA1 | Nb-IgA1 | 26.3 | 27.9 | 23.9 | 16.0 | 4.8 | 1.1 | 0.1 | 1.49 | 100 |
+Nb-P4H1 overexpression | 9.6 | 12.5 | 17.2 | 25.4 | 25.5 | 8.0 | 1.7 | 2.75 | 195 | |
+Nb-P4H4 overexpression | 32.0 | 28.4 | 19.9 | 13.7 | 4.8 | 1.2 | 0.1 | 1.35 | 90 | |
+Nb-P4H9 overexpression | 20.7 | 23.5 | 21.8 | 20.9 | 9.7 | 2.9 | 0.3 | 1.85 | 127 | |
+Nb-P4H10 overexpression | 18.0 | 23.1 | 27.4 | 19.6 | 8.3 | 3.1 | 0.5 | 1.88 | 130 | |
B |
Hyp residues |
av. #Hyp | % change | |||||||
0 | 1 | 2 | 3 | 4 | 5 | 6 | ||||
pEAQ-IgA1 | Nb-IgA1 | 26.3 | 27.9 | 23.9 | 16.0 | 4.8 | 1.1 | 0.1 | 1.49 | 100 |
+Nb-P4H10-RNAi | 35.2 | 31.0 | 19.7 | 6.6 | 4.0 | 1.9 | 1.7 | 1.26 | 83 | |
+Nb-P4H1 and P4H10-RNAi | 31.5 | 31.0 | 20.5 | 10.8 | 4.2 | 1.4 | 0.7 | 1.32 | 87 | |
pPT2M-IgA1 | Nb-IgA1 | 32.2 | 30.7 | 18.8 | 11.4 | 5.2 | 1.5 | 0.3 | 1.33 | 100 |
+Nb-P4H1-RNAi | 23.1 | 30.5 | 23.6 | 14.4 | 6.1 | 1.9 | 0.4 | 1.57 | 119 | |
+Nb-P4H10-RNAi | 36.9 | 31.5 | 17.1 | 8.9 | 4.1 | 1.3 | 0.2 | 1.17 | 88 | |
+Nb-P4H1 and P4H10-RNAi | 50.5 | 27.0 | 13.7 | 6.0 | 2.5 | 0.4 | 0.0 | 0.84 | 64 |
Panel (A) includes the results showing the effect of overexpression of all 4 Nb-P4H proteins (fused to RFP or GFP) on hydroxyproline formation. Panel (B) shows relative quantification results using silencing constructs for Nb-P4H1 and Nb-P4H10. The two different expression vectors (pPT2M and pEAQ, which display maximal expression at different time points) for recombinant production of IgA1 are evaluated separately. Values are presented in percent (%) using the summed peak areas of all observed charge states. The first four isotopic peaks were considered for each of the charge states; in case of ammonium adduct formation only the monoisotopic peak was considered. The average number of Hyp residues per peptide is listed below (av. #Hyp) together with percent increase or decrease (%change) compared to the wild IgA1 construct (Nb-IgA1). The corresponding mass spectra can be found in Supplementary Figure 6 and in Figure 5.